Product Description
AZD1208 is a potent, highly selective, and orally available Pim kinase inhibitor that effectively inhibits all three isoforms at <5 nM or <150 nM in enzyme and cell assays, respectively. AZD1208 inhibited the growth of 5 of 14 acute myeloid leukemia (AML) cell lines tested, and sensitivity correlates with Pim-1 expression and STAT5 activation. (Sourced from: https://ashpublications.org/blood/article/123/6/905/32601/AZD1208-a-potent-and-selective-pan-Pim-kinase)
Mechanisms of Action: PIM Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AstraZeneca
Company Location: Europe
Company Founding Year: 1999
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Acute Myeloid Leukemia|Lymphoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01588548 |
D4510C00005 | P1 |
Completed |
Lymphoma |
2014-07-01 |
2019-03-19 |
||
NCT01489722 |
D4510C00001 | P1 |
Terminated |
Acute Myeloid Leukemia |
2014-05-01 |
2019-03-19 |
Treatments |
|
JapicCTI-121949 |
JapicCTI-121949 | P1 |
Terminated |
Lymphoma |
None |
Recent News Events
Date |
Type |
Title |
|---|